You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Baseline characteristics of 21 included patients

From: FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer

Patient Gender Age TNM Stage Pathology Volume (cm3)
CTV 66Gy BTV FDG 40% BTV FDG 70% BTV FMISO BTV FDG perRT
1 F 51 T3N3M0 IIIB Adenocarcinoma 157.2 21.1 3.0 1.9 18.7
2 M 64 T4N0M0 IIIA Squamous cell carcinoma 512.6 186.5 6.9 75.3 162.0
3 F 59 T1N2M0 IIIA Adenocarcinoma 68.5 9.9 7.6 2.4 2.3
4 M 51 T1N3M0 IIIB Adenocarcinoma 45.8 15.1 2.4 0.1 5.1
5 M 59 T3N3M0 IIIB Adenocarcinoma 273.2 87.2 6.4 8.3 78.7
6 F 60 T3N2M0 IIIA Adenocarcinoma 648.7 189.5 6.1 143.1 132.1
7 M 76 T2N0M0 IIA Squamous cell carcinoma 56.8 13.8 5.0 2.3 2.8
8 F 62 T2N2M0 IIIA Squamous cell carcinoma 116.3 6.3 0.2 4.4 1.1
9 M 63 T4N1M0 IIIA Squamous cell carcinoma 236.1 19.2 0.2 5.7 8.9
10 M 65 T4N2M0 IIIB Squamous cell carcinoma 157.4 14.9 0.3 26.1 9.1
11 M 72 T3N2M0 IIIA Squamous cell carcinoma 289.4 101.1 19.1 272.5 75.8
12 M 59 T4N3M0 IIIB Squamous cell carcinoma 290 37.2 7.6 36.8 15.4
13 M 55 T4N2M0 IIIB Squamous cell carcinoma 970.9 353.2 6.7 100.8 87.6
14 M 58 T4N0M0 IIIB Squamous cell carcinoma 283.7 72.6 15.1 81.1 34.0
15 M 45 T3N2M0 IIIA Squamous cell carcinoma 80.5 30.5 0.4 16.1 9.2
16 M 54 T2N2M0 IIIA Adenocarcinoma 64.4 9.4 0.6 2.4 5.1
17 M 61 T4N2M0 IIIB Squamous cell carcinoma 241.1 22.6 0.9 24.2 64.4
18 M 58 T3N0M0 IIB Unknow 90.4 8.8 2.5 7.9 9.1
19 M 63 T2N2M0 IIIA Adenocarcinoma 328.8 9.5 0.5 1.8 10.2
20 M 70 T3N2M0 IIIA Squamous cell carcinoma 135 24.3 1.6 0.2 4.8
21 M 42 T0N2M0 IIIA Unknow 82.1 29.4 8.0 2.8 19.7
mean   59     244.2 60.1 4.8 38.9 36
SE   8     49.6 18.8 1.1 14.5 10.1